The regulatory sweep found no new approvals, withdrawals or safety communications affecting cardiology practice today.
The standing position that matters most is unchanged. A meta-analysis of 29 randomised trials and 67,873 patients found no class-level association between DPP-4 inhibitors and heart failure events, with a risk ratio of 1.06 and a confidence interval from 0.94 to 1.12. Subgroup analysis again separated saxagliptin, which was associated with increased heart failure risk.
That is the same shape the FDA warning has had since SAVOR-TIMI: a class label carrying a signal that belongs to one or two of its members. For a patient already on a gliptin with heart failure, this supports reviewing which gliptin rather than abandoning the class. It is not new evidence and it should not prompt a letter to patients.
- No new approvals, recalls or safety communications for cardiology today
- Class-level DPP-4 heart failure risk remains unsupported across 67,873 randomised patients
- Saxagliptin remains the exception, consistent with the original FDA labelling
- Alogliptin carries the same labelled warning and was not separated here
- Reasonable prompt to check which gliptin a heart failure patient is actually taking
The statistics, in plain English
A risk ratio of 1.06 with an interval from 0.94 to 1.12 is a genuinely reassuring null: the interval is narrow and sits close to 1.0, so a large class-wide harm has been excluded rather than merely not found. That is a stronger statement than a wide interval containing 1.0, which would only mean the study was too small to tell.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for cardiology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free